John Quisel appointed to Gossamer Bio Board; brings PAH expertise from Acceleron/Merck

Gossamer Bio, Inc.

Appointed Class III director, term expiring at 2024 annual meeting; joins Audit Committee.
Received option to purchase 230,000 shares vesting monthly over three years, plus $40,000 board retainer and $7,500 audit retainer annually.
Currently President & CEO of Disc Medicine; previously at Acceleron Pharma leading re-acquisition of sotatercept rights for PAH from Bristol-Myers Squibb.
Led initiative that culminated in Merck's $11B acquisition of Acceleron in 2021, highlighting deep PAH corporate development experience.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Quisel

Class III Director

GOSS · Gossamer Bio, Inc.

Effective: 2023-11-28
Filed: November 29, 2023, 6:59 PM ET

the Board appointed John Quisel, J.D., Ph.D. to serve as a Class III director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Quisel was appointed as Class III Director at Gossamer Bio, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

the Board appointed John Quisel, J.D., Ph.D. to serve as a Class III director

View on SEC.gov

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-23-000157

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.